Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $6.9000 (-3.36%) ($6.8600 - $7.2000) on Wed. Jun. 12, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.44% (three month average) | RSI | 51 | Latest Price | $6.9000(-3.36%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -0.6% a day on average for past five trading days. | Weekly Trend | TGTX advances 1.3% a week on average for past two weeks. | Market Behavior | Value stocks sell-off for large cap. Normal for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(65%) ARKG(58%) IBB(58%) ARKK(57%) IWO(56%) | Factors Impacting TGTX price | TGTX will decline at least -1.72% in a week (0% probabilities). VXX(-38%) TLT(-9%) UUP(-6%) IFRA(-6%) IGOV(-2%) | | | | | Relative Volatility | | | | Market Trend Strength | -1.72% (StdDev 3.44%) | Hourly BBV | 0 () | Intraday Trend | -3.2% | | | |
|
Resistance Level | $6.94 | 5 Day Moving Average | $7.14(-3.36%) | 10 Day Moving Average | $6.9(0%) | 20 Day Moving Average | $6.94(-0.58%) | To recent high | -18.6% | To recent low | 10% | Market Cap | $874m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |